BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 8903375)

  • 1. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma.
    Hayasaka A; Suzuki N; Fujimoto N; Iwama S; Fukuyama E; Kanda Y; Saisho H
    Hepatology; 1996 Nov; 24(5):1058-62. PubMed ID: 8903375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical usefulness of plasma activities of gelatinase (matrix metalloproteinase-2 and 9) in chronic liver disease].
    Kwon OS; Lim DY; Kwon KA; Chung MG; Park DK; Kim SS; Kim YS; Kwon SY; Koo YS; Kim YK; Choi DJ; Kim JH; Hwang YJ; Byun KS; Lee CH
    Taehan Kan Hakhoe Chi; 2003 Sep; 9(3):222-30. PubMed ID: 14515040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer.
    Endo K; Maehara Y; Baba H; Yamamoto M; Tomisaki S; Watanabe A; Kakeji Y; Sugimachi K
    Anticancer Res; 1997; 17(3C):2253-8. PubMed ID: 9216697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients.
    Iizasa T; Fujisawa T; Suzuki M; Motohashi S; Yasufuku K; Yasukawa T; Baba M; Shiba M
    Clin Cancer Res; 1999 Jan; 5(1):149-53. PubMed ID: 9918213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma matrix metalloproteinase-9 (gelatinase B) in patients with hepatocellular carcinoma.
    Murawaki Y; Ikuta Y; Okamoto K; Mimura K; Koda M; Kawasaki H
    Res Commun Mol Pathol Pharmacol; 2000; 108(5-6):351-7. PubMed ID: 11958288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of serum matrix metalloproteinase (MMP)-9 to MMP-2 ratio as a biomarker in hepatocellular carcinoma.
    Yeh HC; Lin SM; Chen MF; Pan TL; Wang PW; Yeh CT
    Hepatogastroenterology; 2010; 57(97):98-102. PubMed ID: 20422881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential.
    Arii S; Mise M; Harada T; Furutani M; Ishigami S; Niwano M; Mizumoto M; Fukumoto M; Imamura M
    Hepatology; 1996 Aug; 24(2):316-22. PubMed ID: 8690399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between plasma levels of matrix metalloproteinase (MMP)-9 /MMP-2 ratio and alpha-fetoproteins in chronic hepatitis carrying hepatitis B virus.
    Chung TW; Kim JR; Suh JI; Lee YC; Chang YC; Chung TH; Kim CH
    J Gastroenterol Hepatol; 2004 May; 19(5):565-71. PubMed ID: 15086601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.
    Wu CY; Wu MS; Chiang EP; Chen YJ; Chen CJ; Chi NH; Shih YT; Chen GH; Lin JT
    Clin Cancer Res; 2007 Apr; 13(7):2054-60. PubMed ID: 17404086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevation of serum type IV collagen in liver cancer as well as liver cirrhosis.
    Hong WS; Hong SI; Park SY; Son Y; Lee YS; Chung YH; Yang SK; Suh DJ; Min YI
    Anticancer Res; 1995; 15(6B):2777-80. PubMed ID: 8669863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
    Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
    J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma.
    Riedel F; Götte K; Schwalb J; Hörmann K
    Anticancer Res; 2000; 20(5A):3045-9. PubMed ID: 11062721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The predictive ability of serum alpha-fetoprotein for hepatocellular carcinoma is linked with the characteristics of the target population at surveillance.
    Huo TI; Hsia CY; Chu CJ; Huang YH; Lui WY; Wu JC; Lee PC; Chi CW; Lee SD
    J Surg Oncol; 2007 Jun; 95(8):645-51. PubMed ID: 17530668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of cystatin B as a potential serum marker in hepatocellular carcinoma.
    Lee MJ; Yu GR; Park SH; Cho BH; Ahn JS; Park HJ; Song EY; Kim DG
    Clin Cancer Res; 2008 Feb; 14(4):1080-9. PubMed ID: 18281540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
    Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
    Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type IV collagenase/gelatinase (MMP-2) is not increased in plasma of patients with cancer.
    Zucker S; Lysik RM; Zarrabi MH; Stetler-Stevenson W; Liotta LA; Birkedal-Hansen H; Mann W; Furie M
    Cancer Epidemiol Biomarkers Prev; 1992; 1(6):475-9. PubMed ID: 1302560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
    Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
    Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis.
    Wang Y; Liu YH; Mai SJ; He LJ; Liao YJ; Deng HX; Guan XY; Zeng YX; Kung HF; Xie D
    J Gastroenterol Hepatol; 2010 Jun; 25(6):1123-8. PubMed ID: 20594228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis.
    Henry L; Lavabre-Bertrand T; Vercambre L; Ramos J; Carillo S; Guiraud I; Pouderoux P; Bismuth M; Valats JC; Demattei C; Duny Y; Chaze I; Funakoshi N; Bureau JP; Daurès JP; Blanc P
    Gut; 2009 Jun; 58(6):833-8. PubMed ID: 19201777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.